ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.07% | -11.42% | 13.72% | 8.11% | 47.96% |
| Total Depreciation and Amortization | -8.04% | -9.57% | -5.54% | -6.71% | 18.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 207.01% | 140.18% | -8.04% | 282.81% | -95.89% |
| Change in Net Operating Assets | -37.39% | 81.28% | -324.69% | 127.90% | 241.91% |
| Cash from Operations | 5.00% | 9.05% | -87.18% | 82.91% | 59.80% |
| Capital Expenditure | -- | -- | 99.50% | 68.97% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 2,948.30% | -- | -- |
| Cash from Investing | -98.44% | -- | 810.95% | 68.97% | -68.28% |
| Total Debt Issued | 377.75% | -- | -- | -- | -97.87% |
| Total Debt Repaid | -3.49% | 53.67% | 94.91% | -371.32% | 97.28% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 473.81% | 538.63% | 1,549.98% | 281.33% | -98.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.25% | 61.37% | 145.25% | 94.76% | -100.81% |